The IL1R1 Knockout CAL-27 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the IL1R1 gene in the CAL-27 human tongue squamous cell carcinoma line. This pooled format provides a heterogeneous loss-of-function model without clonal selection, enabling population-level studies of IL-1 receptor signaling. The knockout was generated by targeted gene disruption using CRISPR/Cas9, resulting in a mixed population of cells lacking functional IL1R1.
CAL-27 is an epithelial cell line derived from an oral squamous cell carcinoma lesion. It retains aggressive growth and invasive properties characteristic of the tumor of origin, making it a standard model for investigating molecular mechanisms of oral carcinogenesis and testing therapeutic interventions. Its relevance to head and neck oncology is particularly suited to examining the intersection of inflammatory signaling and tumor progression.
IL1R1 encodes the type I interleukin-1 receptor, which initiates pro-inflammatory signaling upon binding of IL1A or IL1B. Ligand engagement recruits the co-receptor IL1RAP, leading to assembly of a signaling complex containing MYD88, IRAK4, IRAK1, and TRAF6. This cascade activates NF-??B (via IKBKB and NFKB1) and MAPK pathways, driving transcription of downstream targets including JUN, FOS, IL6, and IL8. The receptor is negatively regulated by the antagonist IL1RN, positioning IL1R1 as a critical node in cytokine-driven inflammation.
In oral squamous cell carcinoma, aberrant IL1R1 activity promotes tumor-associated inflammation, immune evasion, and enhanced malignancy. By disrupting IL1R1 in CAL-27 cells, this knockout population enables dissection of autocrine and paracrine IL-1 signaling contributions to proliferation, migration, and invasion. It also provides a platform to study interactions between tumor cells and the inflammatory microenvironment, revealing potential therapeutic vulnerabilities.
This knockout cell population is suitable for a wide range of applications, including Western blot analysis of NF-??B pathway components, RT-qPCR quantification of IL6 and IL8 expression, NF-??B luciferase reporter assays, and functional assays for cell migration and invasion under IL-1 stimulation. It is a valuable tool for functional validation of IL1R1, drug target screening for anti-inflammatory therapies, and in-depth mechanistic studies of IL-1-driven signaling in oral cancer. For further information or to discuss custom applications, please contact Ascent Research.
